UnitedHealth Could Reprice Soon: The Catalyst Is Here

James FoordInvesting Group LeaderFollow5ShareSavePlay(6min)CommentsSummaryUnitedHealth Group is rebounding after CMS announced a 2.48% Medicare Advantage reimbursement increase for 2027, reversing market pessimism.This reimbursement shift alleviates worst-case fears, potentially adds $3.9B in revenue and $1B in operating profit potential, and signals regulatory support for sector stability.UNH's scale, integrated Optum platform, and strong balance sheet position it to gain market share as smaller competitors retreat.With forward PE at 14x and historic valuation metrics suggesting 30-50% undervaluation, I remain bullish on UNH despite utilization and political risks.Looking for a helping hand in the market? Members of The Pragmatic Investor get exclusive ideas and guidance to navigate any climate. Learn More » Milan_Jovic/E+ via Getty Images Thesis Summary In my last article, I called UnitedHealth Group (UNH) the best house in a broken neighborhood. While UNH is down a lot in the last year, the problem is not the company, but the wholeThis article was written byJames Foord27.67K FollowersFollowJames Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth.

The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designed to guide investors of all levels in their journey. Features include a The Pragmatic Investor Portfolio, weekly market update newsletter, actionable trades, technical analysis, and a chat room. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of UNH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.